Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients

Boyarsky, Brian J.; Werbel, William A; Avery, Robin K.; Tobian, Aaron A.R.; Massie, Allan B.; Segev, Dorry L.; Garonzik-Wang, Jacqueline

doi:10.1001/jama.2021.7489

Cited by 915 publications

(1,078 citation statements)

References 6 publications

Supporting

Mentioning

967

Contrasting

Unclassified

Order By: Relevance

“…A recent study in JAMA looked at 658 organ transplant recipients and demonstrated a lower antibody response after both doses of the mRNA COVID-19 vaccines when compared to immunocompetent participants 21 . Similarly, early studies suggest that cancer patients do not mount the same antibody responses as healthy controls 22 .…”

Section: Discussionmentioning

confidence: 99%

Immune Responses to COVID-19 mRNA Vaccines in Patients with Solid Tumors on Active, Immunosuppressive Cancer Therapy

Shroff

Chalasani

Wei

et al. 2021

Preprint

View full text Add to dashboard Cite

Vaccines against SARS-CoV-2 have shown high efficacy, but immunocompromised participants were excluded from controlled clinical trials. We evaluated immune responses to the Pfizer/BioNTech mRNA vaccine in solid tumor patients (n=52) on active cytotoxic anti-cancer therapy. These responses were compared to a control cohort that also received the Pfizer/BioNTech vaccine (n=50). Using live SARS-CoV-2 assays, neutralizing antibodies were detected in 67% and 80% of cancer patients after the first and second immunizations, respectively, with a 3-fold increase in median titers after the booster. Similar trends were observed in serum antibodies against the receptor-binding domain (RBD) and S2 regions of Spike protein, and in IFN𝛾+ Spike-specific T cells. The magnitude of each of these responses was diminished relative to the control cohort. We therefore quantified RBD- and Spike S1-specific memory B cell subsets as predictors of anamnestic responses to viral exposures or additional immunizations. After the second vaccination, Spike-specific plasma cell-biased memory B cells were observed in most cancer patients at levels similar to those of the control cohort after the first immunization. These data suggest that a third immunization might elevate antibody responses in cancer patients to levels seen in healthy individuals after the second dose. Trials should be conducted to test these predictions.

show abstract

Section: Discussionmentioning

confidence: 99%

Immune Responses to COVID-19 mRNA Vaccines in Patients with Solid Tumors on Active, Immunosuppressive Cancer Therapy

Shroff

Chalasani

Wei

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…4,5 Initial reports indicate an impaired anti-SARS-CoV-2 antibody response among transplant recipients following mRNA vaccination, likely because of maintenance immunosuppression. 6,7,8,9 Whether kidney transplant recipients have low levels of virus-neutralizing antibody not detected by these assays or protective anti-SARS-CoV-2 T-cell immunity is currently unknown, and the critical question is whether the impaired antibody response corresponds to disease susceptibility. Here, we document 13 cases of COVD-19 in previously vaccinated kidney transplant recipients.…”

Section: To the Editormentioning

confidence: 99%

“…The potential for severe COVID-19 despite vaccination is a concern among transplant recipients, and these cases supplement recent reports that most transplant recipients do not develop a measurable antibody response to standard anti-SARS-CoV-2 mRNA vaccination schedules, although immunogenicity is higher once both doses are administered. 6,7,8,9 It is important to recognize that the efficacy of vaccination without the presence of detectable antibodies is unclear at present, as is the degree of protection afforded by the presence of a detectable anti-spike antibody response. Results from this single-center summary must be reviewed with consideration to the dynamic changes of COVID-19 infections, in the context of community disease transmission and vaccination rates.…”

Section: To the Editormentioning

confidence: 99%

Clinically Significant COVID-19 Following SARS-CoV-2 Vaccination in Kidney Transplant Recipients

Tsapepas

Paget

Mohan

et al. 2021

American Journal of Kidney Diseases

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

“…Nach der zweiten Impfung wurde bei Patient*innen mit soliden Tumoren eine Serokonversion von 95 % erreicht [ 8 ]. Niedrigere Serokonversionsraten nach einmaliger Impfung wurden auch bei Z. n. Organtransplantation beobachtet [ 2 ]. Diese Daten deuten darauf hin, dass bei Verwendung eines mRNA-Impfstoffs die zweite Schutzimpfung bei Krebspatient*innen zeitnah, d. h. nach 3 bzw.…”

Section: Empfehlungen Zur Schutzimpfung Gegen Covid-19 Bei Krebspatient*innenunclassified

Impfung gegen SARS-CoV-2 bei Krebspatienten

Lilienfeld‐Toal¹,

Rieger²,

Giesen

et al. 2021

Onkologe

View full text Add to dashboard Cite

ZusammenfassungPatient*innen mit Krebserkrankungen haben ein erhöhtes Risiko, schwere Verläufe einer COVID-19-Erkrankung zu erleiden. Spezifische Schutzmaßnahmen inkl. der COVID-19-Impfungen sind daher hier von besonderer Bedeutung. Eine durch Therapie und Grunderkrankung oftmals bedingte Abwehrschwäche kann jedoch eine Herausforderung für Impfstrategien bei diesen Patient*innen darstellen. Aktuell sind in Deutschland vier COVID-19-Impfstoffe zugelassen, zwei mRNA- und zwei vektorbasierte Impfstoffe, die alle eine sehr gute Wirksamkeit gegen schwere Krankheitsverläufe zeigen. Hinsichtlich des Wirkmechanismus ist allen vier Impfstoffen die Induktion einer Produktion virusspezifischer Proteine in menschlichen Zellen gemeinsam mit nachfolgender Aktivierung einer adaptiven Immunantwort. Für Krebspatient*innen und medizinisches Personal wird die Impfung priorisiert empfohlen. Ein optimaler Zeitpunkt für die Impfung bei Neuerkrankten scheint vor Beginn einer Tumortherapie zu sein. Aufgrund des erhöhten Risikos von Krebspatient*innen für schwere Verläufe von COVID-19 wird die Impfung jedoch auch unter laufender Tumortherapie empfohlen. Die Impfantwort ist hier allerdings möglicherweise reduziert. In den besonderen Konstellationen einer vorherigen Stammzelltransplantation oder einer B‑Zell-depletierenden Therapie wird nach Möglichkeit ein mehrmonatiger Abstand zwischen Therapie und Impfung empfohlen, da hier ansonsten mit einer deutlich reduzierten Impfantwort gerechnet werden muss. Wenn sich erste Hinweise auf nur eine geringe Serokonversion bei Krebspatient*innen nach einmaliger Impfung bestätigen, können zukünftige Empfehlungen in Richtung mehrfacher Impfungen bei diesen Patient*innen gehen.

show abstract

Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients

Abstract: This follow-up study measures the antibody response following the second dose of SARS-CoV-2 mRNA vaccine in recipients of solid organ transplants.

Cited by 915 publications

References 6 publications

Immune Responses to COVID-19 mRNA Vaccines in Patients with Solid Tumors on Active, Immunosuppressive Cancer Therapy

Immune Responses to COVID-19 mRNA Vaccines in Patients with Solid Tumors on Active, Immunosuppressive Cancer Therapy

Clinically Significant COVID-19 Following SARS-CoV-2 Vaccination in Kidney Transplant Recipients

Impfung gegen SARS-CoV-2 bei Krebspatienten

Contact Info

Product

Resources

About